Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
NuSepin (taurodeoxycholic acid) / Shaperon
NCT05352347 / 2022-001152-42: Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients	Recruiting	2b	1134	RoW	NuSepin® 0.2 mg/kg, NuSepin® 0.4 mg/kg, Placebo	Shaperon, Shaperon, Inc.	COVID-19 Pneumonia	11/24	12/24
NuGel (taurodeoxycholic acid) / Shaperon
NCT06024499: Phase 2 Trial of HY209gel in Atopic Dermatitis Patients	Recruiting	2	210	US	HY209GEL Active, Placebo	Shaperon	Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp	10/25	03/26
BBT-209 / Bridge Biotherap
No trials found
papiliximab / Shaperon
No trials found